Byington v. Vega Biotechnologies, Inc.

869 F. Supp. 338, 1994 U.S. Dist. LEXIS 17355, 1994 WL 679270
CourtDistrict Court, D. Maryland
DecidedNovember 17, 1994
DocketCiv. JFM-93-2989
StatusPublished
Cited by7 cases

This text of 869 F. Supp. 338 (Byington v. Vega Biotechnologies, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Byington v. Vega Biotechnologies, Inc., 869 F. Supp. 338, 1994 U.S. Dist. LEXIS 17355, 1994 WL 679270 (D. Md. 1994).

Opinion

MEMORANDUM

MOTZ, District Judge.

Plaintiffs, S. John Byington, John C. Hilgenberg, Andre R. Brillaud, Paul G. Lowell, Deborah Satterwhite, Jane H. Bennett and Jeanne T. Hugg, are former management employees of Synthecell/Vega Biomoleeules Corporation (“SVB”) a subsidiary of Synthecell Corporation. While asserting myriad claims, plaintiffs essentially allege that their employment was wrongfully terminated after defendants, Charles S. Atkinson, Sr., and Robert Green, wrested control of Synthecell and SVB from them. 1

Defendants have moved to dismiss some of plaintiffs’ claims and have moved for summary judgment as to others.

I.

A.

Plaintiff Byington first became associated with Synthecell when he represented it as a member of á law firm that served as its outside counsel. In early 1991, he became Synthecell’s general counsel. In February 1992, he was appointed as president and chief operating officer of Synthecell and all of its subsidiaries, including SVB. Byington had a written employment agreement for the period February 1, 1992 to June 30, 1996 at an annual salary of $180,000 plus annual adjustments. As further compensation, he was to receive periodic stock options, performance bonuses and other incentives. The agreement provided that Byington’s employment could be terminated without cause by a simple majority of the directors of Synthecell, but in that event Byington would be entitled to receive substantial liquidated damages. The agreement further provided that Byington’s employment could be terminated for cause either upon his conviction of a felony or if two-thirds of Synthecell’s directors “in good faith determined, in its sole discretion, that ... [Byington] is guilty of willful breach of this Agreement, habitual neglect of [his] duties under this Agreement or gross mismanagement of the Company.” If Byington was terminated for cause, he had no right to receive any additional compensation or other benefits.

Hilgenberg served as the chief executive officer of Synthecell, the chief financial officer of both Synthecell and SVB and as a director of Synthecell. Brillaud served as the executive vice-president of operations for SVB. Lowell served as the vice-president for corporate development of Synthecell and *341 SVB. Satterwhite served as the vice-president of operations for SVB. Bennett worked for SVB as an executive assistant. Hugg served as SVB’s director of human resources. All of these plaintiffs had substantial compensation packages, including salaries ranging from $40,000 for Bennett to $130,000 for Hilgenberg, plus stock options and bonuses.

B.

Synthecell acquired its controlling interest in SVB in February 1992. Both companies were losing money at the time, but Synthecell projected that it would reach profitability by July 1992 and remain profitable thereafter. It was also projected that Synthecell would receive from $2 million to $4 million in new equity.

Unfortunately, none of these projections proved true. At the beginning of August 1993 (the month in which the employment of plaintiffs was terminated) Synthecell and SVB had only a little more than $10,000 in cash on hand and had to discharge obligations totalling more than $40,000 by August 6. The companies hoped to receive $50,000 in collections by mid-month, but $73,-000 in debts were to become due early in the week of August 9. Furthermore, the companies were accruing payroll and related expenses at the rate of $231,000 per month; these expenses were projected to leave the companies with a cash shortfall of $340,000 by the end of August. In addition, one of the companies’ vendors had announced that it would repossess its equipment on August 12 unless it was paid approximately $122,000.

To make matters worse, Hoffman-LaRoehe, the companies’ largest customer which accounted for over 50% of their monthly business, had suspended all of its orders. In light of this development, it was projected that the companies, after having lost $1 million during the first six months of 1993, would lose from $200,000 to $300,000 per month for the rest of the year.

The efforts made by Byington and other members of senior management to raise new capital had been unsuccessful. As a result, at the end of 1992 and early in 1993 Byington, on behalf of Synthecell, entered into negotiations to sell the controlling interest in another Synthecell subsidiary, Genetic MediSyn Corporation, to Medicis Pharmaceuticals. The initial closing of this transaction, scheduled for February 1993, failed, in part because a member of the Medicis negotiating team believed that Byington had made misrepresentations to him. In order to resurrect the deal, Synthecell’s board relieved Byington of his negotiating duties and substituted defendant Green in his stead. With the assistance of plaintiff Lowell, Green resumed the negotiations and brought them to a conclusion. However, Synthecell was not in a strong negotiating position because of its need for cash; therefore, the proceeds of the sale were substantially less than Synthecell had hoped ($1.8 million instead of $4 million).

SVB entered into a letter agreement with Midwood Securities, Inc. in February 1993, calling for Midwood to serve as SVB’s agent and privately placing approximately $8 million in securities. During the same month, CIT Group/Venture Capital, Inc. (“CIT”) submitted a proposed term sheet, stating conditions under which it would contemplate serving as the lead or co-lead investor in the private placement.

By a memorandum dated February 25, 1993, Byington advised Synthecell’s board that he anticipated that the private placement would close by April 15,1993. This did not occur and on April 16, Byington sent a note to a number of directors stating that “Paul [Laud of CIT] and Park [Benjamin of Midwood] believe that we are still on target for funding by the end of the month.” Again, the deal did not close as projected, and Synthecell and SVB had to obtain a bridge loan to finance their operations until the completion of the private placement. In a memorandum to the directors on April 30, 1993, Byington stated that “[w]e expect that funding to occur in May, but we have built in the necessary contingencies unless it takes until early June.”

By the middle of June, the private placement still had not closed. On June 18, Byington and Lowell attended a meeting in the offices of Paul Laud of CIT in New York. Also participating in the meeting were representatives of CIT, Midwood and Venkol, Inc., *342 another potential investor. During the meeting CIT conditioned its investment on SVB’s ability to raise at least $5.5 million and to secure the participation of a third institutional investor (in addition to itself and Venkol).

By a memorandum dated June 21, 1993, Byington advised SVB’s board of efforts to bring the “third institutional investor ... to the table” by the end of the month. These efforts did not bear fruit, and in a memorandum dated June 28, 1993, he stated that SVB did “not have the third institutional investor at $1.5 million required by Venkol and CIT.” He further stated:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McREADY v. O'MALLEY
804 F. Supp. 2d 427 (D. Maryland, 2011)
Hildebrandt v. W.R. Grace & Co.-Conn.
492 F. Supp. 2d 516 (D. Maryland, 2007)
Berman v. Physical Medicine Associates, Ltd.
225 F.3d 429 (Fourth Circuit, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
869 F. Supp. 338, 1994 U.S. Dist. LEXIS 17355, 1994 WL 679270, Counsel Stack Legal Research, https://law.counselstack.com/opinion/byington-v-vega-biotechnologies-inc-mdd-1994.